Table 2.

ORs for human papillomavirus detection (any type) according to menstrual phase and oral contraceptive pill use for cumulative patient visits^*

OC Use	Positive/total samples, n (all phases)	Age-adjusted OR (95% CI)
		5–9 days (46/315, 14.6%)	10–15 days (65/344, 18.9%)	16–22 days (63/328, 19.2%)	23–31 days (46/264, 17.4%)
Never user	148/863	1.0 (ref) (31/210, 14.8%)	1.19 (0.71–2.01) (39/236, 16.5%)	1.40 (0.85–2.31) (47/239, 19.7%)	1.07 (0.62–1.86) (31/183, 16.9%)
Current user	72/383	1.0 (ref) (15/105, 14.3%)	1.86 (0.93–3.77) (26/108, 24.0%)	1.32 (0.61–2.85) (16/89, 18.0%)	1.32 (0.60–2.91) (15/81, 18.5%)
<6 years	51/236	1.0 (ref) (10/61, 16.4%)	1.82 (0.76–4.39) (17/64, 26.6%)	1.48 (0.58–3.78) (12/54, 22.2%)	1.42 (0.56–3.60) (12/57, 21.0%)
≥6 years	21/147	1.0 (ref) (5/44, 11.4%)	2.03 (0.61–6.70) (9/44, 20.4%)	1.00 (0.25–4.04) (4/35, 11.4%)	1.11 (0.24–5.17) (3/24, 12.5%)

All p values were non-significant at 0.05 level of testing.

^*ORs calculated with logistic regression using generalised estimating equations implementation.

OC, oral contraceptive.